Literature DB >> 20112392

Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist.

Céline Lamacchia1, Gaby Palmer, Christian A Seemayer, Dominique Talabot-Ayer, Cem Gabay.   

Abstract

OBJECTIVE: The balance between interleukin-1 (IL-1) and its specific inhibitor, the IL-1 receptor antagonist (IL-1Ra), plays a major role in the development of arthritis. The purpose of this study was to investigate the role of IL-1Ra produced specifically by myeloid cells in the control of collagen-induced arthritis (CIA) by using myeloid cell-specific IL-1Ra-deficient mice (IL-1Ra(DeltaM)).
METHODS: IL-1Ra(DeltaM) mice were generated by using the loxP/Cre recombinase system. CIA was induced in IL-1Ra(DeltaM) mice and littermate control mice by a single immunization with bovine type II collagen (CII) in Freund's complete adjuvant. Arthritis severity was assessed by clinical and histologic scoring. Draining lymph node (DLN) cell responses were examined ex vivo, and ankle extracts were used in the quantification of cytokines and chemokines.
RESULTS: Clinical and histopathologic evaluations revealed an early disease onset and a severe form of CIA in IL-1Ra(DeltaM) mice. This was characterized by increased production of interferon-gamma (IFNgamma) and IL-17 by CII-stimulated DLN cells. We also observed that the CII-specific CD4+ T cell response shifted in vivo, from a dominant Th1 response early in the course of the arthritis to the presence of both Th1 and Th17 cytokines later in the disease course. Interestingly, IL-1Ra levels were higher in the arthritic joints of IL-1Ra(DeltaM) mice as compared with the controls, indicating that nonmyeloid cells strongly contribute to the local production of IL-1Ra. However, this enhanced IL-1Ra production was not sufficient to limit joint inflammation and tissue damage.
CONCLUSION: Our results suggest that myeloid cell-derived IL-1Ra plays a critical role in the control of the development and the severity of CIA by modulating Th1 and Th17 responses in lymphoid organs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112392     DOI: 10.1002/art.27235

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

1.  Active Hexose Correlated Compound promotes T helper (Th) 17 and 1 cell responses via inducing IL-1β production from monocytes in humans.

Authors:  Won-Woo Lee; Naeun Lee; Hajime Fujii; Insoo Kang
Journal:  Cell Immunol       Date:  2012-04-06       Impact factor: 4.868

2.  Mutations in the IL1RN locus lead to autoinflammation.

Authors:  Cem Gabay; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2009-09       Impact factor: 20.543

Review 3.  Dysregulation of T cell subsets in the pathogenesis of hypertension.

Authors:  Songcang Chen; Devendra K Agrawal
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

4.  Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis.

Authors:  Kira Minkis; Ivona Aksentijevich; Raphaela Goldbach-Mansky; Cynthia Magro; Rachelle Scott; Jessica G Davis; Niti Sardana; Ronit Herzog
Journal:  Arch Dermatol       Date:  2012-06

Review 5.  Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis.

Authors:  Gianfranco Ferraccioli; Luisa Bracci-Laudiero; Stefano Alivernini; Elisa Gremese; Barbara Tolusso; Fabrizio De Benedetti
Journal:  Mol Med       Date:  2010-08-02       Impact factor: 6.354

Review 6.  Th17 cell cytokine secretion profile in host defense and autoimmunity.

Authors:  Kristen E Graeber; Nancy J Olsen
Journal:  Inflamm Res       Date:  2011-12-25       Impact factor: 4.575

7.  Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice.

Authors:  Xiaorong Zhou; Xing Hua; Xiaoling Ding; Yonghua Bian; Xiaoying Wang
Journal:  J Clin Immunol       Date:  2011-02-09       Impact factor: 8.317

Review 8.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

Review 9.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

10.  Visualization and phenotyping of proinflammatory antigen-specific T cells during collagen-induced arthritis in a mouse with a fixed collagen type II-specific transgenic T-cell receptor β-chain.

Authors:  Patrick Merky; Tsvetelina Batsalova; Robert Bockermann; Balik Dzhambazov; Bettina Sehnert; Harald Burkhardt; Johan Bäcklund
Journal:  Arthritis Res Ther       Date:  2010-08-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.